voglibose/metformin / Generic mfg. - LARVOL DELTA

4 Diabetes Medication FDCs Including Glimipride Metformin Strength Banned By Health Ministry (Medical Dialogues) - "The Central Drugs Standard Control Organization (CDSCO) has banned the manufacture, sale, and distribution of certain widely used strengths of fixed dose combinations (FDCs) in the anti-diabetic segment. These FDCs, including popular oral therapies combining metformin, glimepiride, voglibose, and dapagliflozin, were previously licensed by various State Licensing Authorities (SLAs) without due approval or evaluation by the Drugs Controller General of India (DCGI)....Among the Antidiabetic agents, strengths of FDCs listed as either cancelled or voluntarily surrendered following show-cause notices are: Metformin Hydrochloride IP 500mg (as extended release form) + Glimepiride IP 3mg + Dapagliflozin Propanediol Monohydrate IP eq. to Dapagliflozin 10mg film coated bilayered tablets; Glimepiride IP 1mg & Metformin HCL IP 500mg Tablet; Glimepiride IP 2mg, Metformin Hydrochloride IP (As Sustained Release form) 500mg and Voglibose IP 0.3mg Tablet; Metformin Hydrochloride..."

Commercial • Diabetes

Antioxidant, Alpha-Amylase Inhibitory and Hypoglycemic Activity of Smallanthus sonchifolius Leaves from Nepal: An Integrated In Vitro, In Vivo, and In Silico Approach. (PubMed, Food Sci Nutr) - "The ethanolic extract exhibited dose-dependent alpha-amylase inhibition (IC50 value 0.136 mg/mL) and significant hypoglycemic effects, reducing blood glucose levels similar to those of the standard drugs voglibose and metformin. Polymatin B and chlorogenic acid showed strong binding affinities of -7.3 and -7.5 kcal/mol, respectively, in alpha-amylase (4W93). These findings indicate that S. sonchifolius possesses significant hypoglycemic and antioxidant properties, suggesting its potential as an antidiabetic agent, warranting further clinical research."

Journal • Preclinical • Diabetes • Metabolic Disorders

Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management. (PubMed, Cureus) - "The most prescribed FDC was 1 mg glimepiride, 500 mg metformin, 0.2 mg voglibose (40.14%), the most preferred dosing frequency was once daily (52.92%) and the most common duration of treatment was one to three months (48.78%). Conclusion In routine Indian clinical practice, the triple drug FDC of 1 mg glimepiride, 500 mg metformin, and 0.2 mg voglibose, taken once daily for one to three months, was the most common treatment for both newly diagnosed and long-standing diabetes patients."

Journal • Retrospective data • Diabetes • Dyslipidemia • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

VMGMProtocol: Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (clinicaltrials.gov) - P3 | N=118 | Not yet recruiting | Sponsor: University of Zambia | Trial completion date: Jul 2023 ➔ Jan 2024 | Initiation date: Jan 2023 ➔ Aug 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

VMGMProtocol: Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (clinicaltrials.gov) - P3 | N=118 | Not yet recruiting | Sponsor: University of Zambia

New P3 trial • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

"Dominus Vobiscum Double BEER 🍺🍻https://t.co/paTDS261fR" (@VHNguyenMD)